Genmab A/S (GMAB) Stock Forecast & Price Target

$20.31 +0.22 (+1.10%)

(As of 12/20/2024 05:16 PM ET)

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
1

Hold
2

Buy
6

Based on 9 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 2 have given a hold rating, and 6 have given a buy rating for GMAB.

Consensus Price Target

$45.20
122.55% Upside

According to the 9 analysts' twelve-month price targets for Genmab A/S, the average price target is $45.20. The highest price target for GMAB is $50.00, while the lowest price target for GMAB is $31.00. The average price target represents a forecasted upside of 122.55% from the current price of $20.31.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

GMAB Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$45.20	$45.20	$45.20	$46.25
Forecasted Upside	122.55% Upside	118.89% Upside	87.24% Upside	47.11% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	122.55% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent GMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$46.00 ➝ $48.00	+110.25%
10/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00	+115.70%
10/8/2024	Redburn Atlantic 5 of 5 stars	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$31.00 ➝ $31.00	+15.63%
9/9/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$53.00 ➝ $50.00	+82.55%
8/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/18/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
2/23/2023	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$33.00 ➝ $36.00	-5.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:01 PM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

Recent increase in short interest by 23.2% indicates heightened market activity and potential for price volatility, which can create trading opportunities.
Current stock price is $20.59, which is near its 12-month low of $20.50, suggesting a potential buying opportunity for investors looking for undervalued stocks.
Institutional investors have shown strong interest, with significant increases in holdings, indicating confidence in the company's future performance.
Genmab A/S reported a net margin of 23.49%, reflecting strong profitability and efficient management of expenses relative to revenue.
The company has a solid return on equity of 14.64%, demonstrating effective use of shareholders' equity to generate profits.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

The company missed earnings expectations, reporting $0.29 EPS against a consensus estimate of $0.32, which may raise concerns about its growth trajectory.
Revenue for the latest quarter was $816.10 million, falling short of analyst expectations of $838.20 million, indicating potential challenges in meeting market demands.
Genmab A/S has experienced a decline in stock price, trading down 2.8% recently, which may signal investor uncertainty or market volatility.
With only 7.07% of the stock owned by institutional investors, there may be less institutional support compared to other companies, which can affect stock stability.
The stock has a relatively high price-to-earnings (P/E) ratio of 19.99, which could suggest that it is overvalued compared to its earnings, making it a riskier investment.

GMAB Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $45.20, with a high forecast of $50.00 and a low forecast of $31.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There is currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMAB shares.
: According to analysts, Genmab A/S's stock has a predicted upside of 122.55% based on their 12-month stock forecasts.
: Genmab A/S has been rated by research analysts at BMO Capital Markets, HC Wainwright, and Redburn Atlantic in the past 90 days.
: Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.56 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This is the worst sign for the U.S. stock market in 50 years (Ad)

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

This page (NASDAQ:GMAB) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Stock Forecast & Price Target